Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Company Overview
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, acquisition, development, and commercialization of novel therapeutic candidates. The company is strategically positioned in the fields of immunology, inflammation, and oncology, utilizing an asset-rich in-licensing model that leverages the deep experience of its founding team. This approach focuses on targeting high unmet needs among patient populations with conditions that are complex and challenging to manage, ensuring that Gossamer Bio remains relevant in addressing critical healthcare issues.
Core Business Areas
The company’s operations are centered on identifying and advancing therapeutic candidates that address key disease mechanisms such as cellular overgrowth, fibrosis, and dysregulated vascular remodeling. By focusing on immunology, inflammation, and oncology, Gossamer Bio develops treatments aimed at conditions including pulmonary arterial hypertension, inflammatory bowel diseases like ulcerative colitis and Crohn’s disease, specific oncology indications, and moderate-to-severe respiratory conditions such as eosinophilic asthma. Its expert research and development team capitalizes on proven methodologies in drug discovery, ensuring that each candidate is backed by comprehensive preclinical and clinical evaluation.
Gossamer Bio (Nasdaq: GOSS) has announced the approval of inducement grants under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee of Gossamer's Board of Directors has approved non-qualified stock option awards for one non-executive employee to purchase up to 55,000 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The options, granted on April 7, 2025, have an exercise price of $0.82 per share, matching the closing price of Gossamer's common stock on Nasdaq Global Select Market. The options feature a ten-year term with a four-year vesting schedule: 25% vesting after one year, followed by the remaining balance vesting in 36 monthly installments, contingent on continued employment.
Gossamer Bio (NASDAQ: GOSS) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its pulmonary hypertension drug development programs. The company's lead candidate, seralutinib, is advancing with the PROSERA Phase 3 trial in PAH, with topline data expected in Q4 2025.
Key developments include seralutinib receiving Orphan Drug Designation in Japan for PAH treatment and plans to initiate a registrational Phase 3 trial for PH-ILD in H2 2025. The company ended 2024 with $294.5 million in cash and equivalents, expected to fund operations into H1 2027.
Financial highlights for 2024 include: R&D expenses of $138.5 million (vs $135.3M in 2023), G&A expenses of $36.1 million (vs $38.5M in 2023), and a significantly reduced net loss of $56.5 million or $0.25 per share (compared to $179.8M or $1.18 per share in 2023).
Gossamer Bio (Nasdaq: GOSS) has announced the approval of inducement grants to five non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved non-qualified stock option awards to purchase up to 342,250 shares of common stock, effective March 5, 2025.
The options were granted at an exercise price of $1.18 per share, matching the closing price of Gossamer's common stock on March 5, 2025. These ten-year term options will vest over four years, with 25% vesting on the one-year anniversary and the remaining balance vesting in 36 monthly installments, contingent on continued employment.
Gossamer Bio (NASDAQ: GOSS) has announced the approval of inducement grants under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved non-qualified stock options for three non-executive employees to purchase up to 510,000 shares of common stock, effective February 5, 2025.
The options have an exercise price of $1.15 per share, matching the closing price of Gossamer's stock on February 5, 2025. These ten-year options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment. The grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Gossamer Bio (NASDAQ: GOSS) presented clinical and preclinical data for seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress in Rio de Janeiro, Brazil. The presentations included one oral presentation and three posters focusing on seralutinib, an inhaled PDGFR, CSF1R and c-KIT inhibitor being developed for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The posters covered preclinical models demonstrating synergistic potential with sotatercept, sustained benefits observed in the TORREY open-label extension study, and the drug's sustained effect on circulating biomarkers.
Gossamer Bio (NASDAQ: GOSS) announced presentations of clinical and preclinical data for seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress in Rio de Janeiro. The company will showcase one oral and three poster presentations highlighting seralutinib's potential in treating pulmonary arterial hypertension (PAH).
Key highlights include preclinical evidence demonstrating synergistic effects when combining seralutinib with sotatercept, a recently approved PAH therapy. The company's ongoing global Phase 3 PROSERA Study allows for patient enrollment on stable sotatercept background treatment and permits other enrolled patients to add sotatercept after 24 weeks where approved.
The presentations will feature data from preclinical models, post-hoc analysis of the TORREY open-label extension, and sustained effects on circulating biomarkers, building upon positive Phase 2 TORREY Study results where most patients were on triple background PAH therapy.
Gossamer Bio (GOSS) has announced the approval of inducement grants to three non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved non-qualified stock options to purchase up to 225,000 shares of common stock, effective January 6, 2025.
The options have an exercise price of $1.09 per share, matching the closing price of Gossamer's stock on Nasdaq Global Select Market on January 6, 2025. These ten-year options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment.
Gossamer Bio (Nasdaq: GOSS) announced that its Compensation Committee approved stock option grants to two new non-executive employees under the 2023 Employment Inducement Incentive Award Plan. The grants total 183,000 shares with an exercise price of $0.88 per share, matching Nasdaq's closing price on November 8, 2024. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Gossamer Bio (GOSS) reported Q3 2024 financial results with $327.0 million in cash and equivalents as of September 30, 2024. The company posted revenue of $9.5 million from collaborator contracts, R&D expenses of $34.9 million, and a net loss of $30.8 million ($0.14 per share). The company expects current funds to sustain operations into H1 2027.
The company continues enrollment in the PROSERA Study, a Phase 3 trial for seralutinib in PAH patients, with topline results expected in Q4 2025. Additionally, Gossamer plans to initiate a Phase 3 trial for PH-ILD treatment in mid-2025.
Gossamer Bio, a clinical-stage biopharmaceutical company, announced the approval of non-qualified stock option awards for five new non-executive employees. The Compensation Committee of Gossamer's Board of Directors granted options to purchase up to 221,000 shares of the company's common stock under the 2023 Employment Inducement Incentive Award Plan. These awards, granted on October 4, 2024, are in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.07 per share, equal to the closing price of Gossamer's common stock on the grant date. They have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 monthly installments, subject to continued employment.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
What is Gossamer Bio's core business focus?
How does Gossamer Bio generate revenue?
What therapeutic areas does the company target?
How does the company differentiate itself from competitors?
What is the significance of focusing on high unmet needs?
What role does the company’s clinical-stage status play in its operations?
